Relief in Gastrointestinal Symptoms with Medical Marijuana Over 1 Year.

Q1 Medicine Medical Cannabis and Cannabinoids Pub Date : 2024-04-16 eCollection Date: 2024-01-01 DOI:10.1159/000538694
Matthew P Wallingford, Erin L Kelly, Allison Herens, Daniel Hanna, Emily Hajjar, Brooke Worster
{"title":"Relief in Gastrointestinal Symptoms with Medical Marijuana Over 1 Year.","authors":"Matthew P Wallingford, Erin L Kelly, Allison Herens, Daniel Hanna, Emily Hajjar, Brooke Worster","doi":"10.1159/000538694","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Subjective improvement in gastrointestinal (GI) symptoms was assessed among patients using medical marijuana (MMJ).</p><p><strong>Methods: </strong>Participants completed surveys at 0 days, 30 days, 6 months, and 12 months with questions about the severity of their GI symptoms on a scale from 1 (mild) to 3 (severe).</p><p><strong>Results: </strong>In each survey, participants reported a significant decrease in GI symptom severity when using MMJ versus when not using MMJ (<i>p</i> < 0.05). The most common self-reported side effects from using MMJ were increased appetite (12-21.4%), fatigue (6-16.7%), anxiety (4-11.9%), cough (4-11.9%), headache (6-7.9%), and dry mouth (4-7.1%).</p><p><strong>Conclusion: </strong>In patients with chronic GI symptoms, MMJ may provide persistent symptom severity improvement. Limited product availability and mild to moderate side effects are factors to consider before trialing MMJ.</p>","PeriodicalId":18415,"journal":{"name":"Medical Cannabis and Cannabinoids","volume":"7 1","pages":"80-85"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250604/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Cannabis and Cannabinoids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000538694","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Subjective improvement in gastrointestinal (GI) symptoms was assessed among patients using medical marijuana (MMJ).

Methods: Participants completed surveys at 0 days, 30 days, 6 months, and 12 months with questions about the severity of their GI symptoms on a scale from 1 (mild) to 3 (severe).

Results: In each survey, participants reported a significant decrease in GI symptom severity when using MMJ versus when not using MMJ (p < 0.05). The most common self-reported side effects from using MMJ were increased appetite (12-21.4%), fatigue (6-16.7%), anxiety (4-11.9%), cough (4-11.9%), headache (6-7.9%), and dry mouth (4-7.1%).

Conclusion: In patients with chronic GI symptoms, MMJ may provide persistent symptom severity improvement. Limited product availability and mild to moderate side effects are factors to consider before trialing MMJ.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用医用大麻缓解胃肠道症状超过 1 年。
介绍:对使用医用大麻(MMJ)的患者胃肠道(GI)症状的主观改善情况进行评估:参试者分别在服药 0 天、30 天、6 个月和 12 个月时填写了调查问卷,调查内容为胃肠道症状的严重程度,评分标准从 1 分(轻微)到 3 分(严重):在每次调查中,参与者都报告说,使用 MMJ 与不使用 MMJ 相比,胃肠道症状的严重程度明显减轻(P < 0.05)。使用五味子大麻最常见的自我报告副作用是食欲增加(12-21.4%)、疲劳(6-16.7%)、焦虑(4-11.9%)、咳嗽(4-11.9%)、头痛(6-7.9%)和口干(4-7.1%):结论:对于有慢性消化道症状的患者,MMJ 可以持续改善症状的严重程度。有限的产品供应和轻度至中度的副作用是试用 MMJ 之前需要考虑的因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medical Cannabis and Cannabinoids
Medical Cannabis and Cannabinoids Medicine-Complementary and Alternative Medicine
CiteScore
6.00
自引率
0.00%
发文量
18
审稿时长
18 weeks
期刊最新文献
Proceedings of the 2024 Cannabis Clinical Outcomes Research Conference. Development and in vitro Evaluation of Cannabidiol Mucoadhesive Buccal Film Formulations Using Hot-Melt Extrusion Technology. Cannabinoids for the Treatment of Glaucoma: A Review. Long-Term Treatment for Unspecified Anxiety Disorders with Cannabidiol: A Retrospective Case Series from Real-World Evidence in Colombia. Use of Cannabidiol-Dominant Extract as Co-Adjuvant Therapy for Type 2 Diabetes Mellitus Treatment in Feline: Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1